AbbVie said it will invest $195 million to expand its active pharmaceutical ingredient manufacturing capacity in Illinois, deepening a multi-year plan to plough $10 billion into its U.S. operations. Construction of the new facilities is scheduled to begin in the fall of 2025, with commercial operations targeted for 2027. The project will add production lines for APIs, drug product, peptides and medical devices, enhancing domestic supply of critical inputs for the company’s pipeline medicines. Illinois Governor J.B. Pritzker welcomed the decision, saying it affirms the state’s biomanufacturing strengths and will generate new jobs. Lawmakers hailed the move as further evidence of efforts to shore up the nation’s pharmaceutical supply chain.